Pros
Had daily interaction with medical and technology leaders at the top-tier medical and research institutions in Canada, the US, and Europe. Our team achieved the world's first approval for a clinical molecular imaging device that didn't require contrast agents. Our important contributions to breast cancer research and pharmaceutical development were recognized with many industry awards. Investors included the most respected fund managers in Canada and the US. CEO leadership was smart, committed, and fair.
Cons
Challenging conditions in the public equity markets limited progress in key areas and necessarily required a short-term focus.
